ArticleFrontiers in cell and developmental biology2025
A novel proliferation synergy factor cocktail maintains proliferation and improves transfection efficiency in muscle cells and fibroblasts under low-serum conditions.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-serum culture systems offer enhanced controllability, improved safety, and increased cost-effectiveness for applications in tissue engineering, regenerative medicine, drug screening, and cultured meat production. In this study, we developed a novel proliferation synergy factor cocktail (PSFC) consisting of IGF-1, bFGF, TGF-β, IL-6, and G-CSF under low-serum (5% FBS) conditions. This system not only sustained robust proliferation of porcine muscle satellite cells (PSCs) and porcine kidney fibroblasts (PKFs), but also exhibited broad applicability in C2C12 myoblasts and mouse skeletal muscle satellite cells (SSCs). RT-qPCR and Western blot showed that there were no significant differences in the expression levels of the proliferation marker Ki67, as well as the myogenic regulatory factors MyoG and MyHC, between the 5% FBS-PSFC culture system and the conventional serum culture system. Notably, PSFC supplementation enhanced the average transfection efficiency by 16.9% across all tested cell types. Furthermore, the 5% FBS-PSFC platform facilitated three-dimensional (3D) culture within gelatin methacryloyl (GelMA) hydrogels, enabling scalable cultured meat production while reducing serum costs by 75%. Further RNA-seq analysis revealed that the there was no significant changes in the expression of cell proliferation-related genes which may be crucial for maintaining cell proliferation of this system, while the upregulation of genes associated with membrane fluidity and endocytosis, such as
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.